Drug:
Reaction: MALIGNANT NEOPLASM PROGRESSION
20260101 - 20261231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 26940335 |
AU |
1 | |
Malignant neoplasm progression, Splenomegaly, Liver function test increased, |
||||
| 2 | 26940496 |
EU |
1 | |
Polycythaemia vera, Malignant neoplasm progression, Acute leukaemia, |
||||
| 3 | 26941044 |
JP |
1 | |
Pneumocystis jirovecii pneumonia, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 4 | 26941436 |
US |
87 | 2 |
Malignant neoplasm progression, Pneumothorax, |
||||
FULVESTRANT, FULVESTRANT, PALBOCICLIB, PALBOCICLIB, PALBOCICLIB, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, BISOPROLOL FUMARATE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, |
||||
| 5 | 26941524 |
KH |
2 | |
Cholelithiasis, Chronic myeloid leukaemia, Malignant neoplasm progression, Vaginal haemorrhage, Uterine haemorrhage, Haematochezia, Hypothyroidism, Malaise, Diabetes mellitus, Loose tooth, Blood creatinine decreased, Varicose vein, Drug intolerance, Cardiac disorder, Crying, Transferrin saturation decreased, Blood cholesterol increased, Microalbuminuria, White blood cell count increased, Prothrombin time shortened, Blood lactate dehydrogenase abnormal, Lymphocyte count abnormal, Antinuclear antibody positive, Blood triglycerides increased, Product dose omission issue, Iron deficiency anaemia, Alanine aminotransferase abnormal, Aspartate aminotransferase abnormal, Manganese increased, Neutrophil count increased, Mean cell haemoglobin concentration abnormal, Neck pain, Back pain, Pallor, Ocular hyperaemia, Pain, Peripheral swelling, Oedema peripheral, Normochromic normocytic anaemia, Hepatomegaly, Dyslipidaemia, Hyperglycaemia, Hepatic steatosis, Arthralgia, Pain in extremity, Chest pain, Haemoglobin decreased, Anaemia, Dyspnoea, Anxiety, Tachycardia, White blood cell count abnormal, Cough, Blood pressure increased, Blood iron decreased, Cytogenetic analysis abnormal, Hypertension, Depression, |
||||
METFORMIN, METFORMIN ER 500 MG, METFORMIN ER 750 MG, NILOTINIB, DICLOFENAC, DICLOFENAC SODIUM, DIPHENHYDRAMINE, DIPHENHYDRAMINE HYDROCHLORIDE, MAGNESIUM SULFATE, MAGNESIUM SULFATE HEPTAHYDRATE, MAGNESIUM SULFATE IN WATER FOR, CALCIUM, |
||||
| 6 | 26941547 |
EU |
2 | |
Thrombocytopenia, Neutropenia, Malignant neoplasm progression, |
||||
DURVALUMAB, CARBOPLATIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
| 7 | 26941668 |
EU |
66 | |
Epilepsy, Malignant neoplasm progression, Metastatic renal cell carcinoma, |
||||
CABOZANTINIB, CABOZANTINIB, NIVOLUMAB, |
||||
| 8 | 26941895 |
CH |
1 | |
Malignant neoplasm progression, |
||||
RIPRETINIB, |
||||
| 9 | 26942036 |
EU |
69 | 1 |
Malignant neoplasm progression, Diarrhoea, |
||||
CARBOPLATIN, PEMBROLIZUMAB, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, FUROSEMIDE, BISOPROLOL FUMARATE, ALLOPURINOL, |
||||
| 10 | 26942068 |
CN |
67 | 2 |
White blood cell count decreased, Fatigue, Myelosuppression, Discomfort, Oropharyngeal pain, Malignant neoplasm progression, Platelet count decreased, Haemoglobin decreased, |
||||
VENETOCLAX, SELINEXOR, CYTARABINE, AZACITIDINE, AZACITIDINE FOR, |
||||
| 11 | 26942194 |
EU |
65 | |
Malignant neoplasm progression, Metastases to liver, Diarrhoea, |
||||
GOSERELIN, GOSERELIN, CAPIVASERTIB, |
||||
| 12 | 26942278 |
IN |
66 | 2 |
Breast cancer metastatic, Malignant neoplasm progression, Neutropenia, Blood creatinine increased, Positron emission tomogram abnormal, Lymphadenopathy, Breast calcifications, Skin hypertrophy, Off label use, |
||||
RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, |
||||
| 13 | 26943082 |
BR |
40 | |
General physical health deterioration, Malignant neoplasm progression, Vomiting, Diarrhoea, |
||||
CETUXIMAB, CETUXIMAB, |
||||
| 14 | 26943084 |
AU |
||
Malignant neoplasm progression, |
||||
OSIMERTINIB, OSIMERTINIB, |
||||
| 15 | 26943385 |
HK |
70 | 1 |
Gastrointestinal haemorrhage, Hepatic cirrhosis, Hepatitis B, Spontaneous bacterial peritonitis, Chronic myeloid leukaemia, Malignant neoplasm progression, Varices oesophageal, Thrombocytopenia, Cytopenia, Drug ineffective, |
||||
IMATINIB, IMATINIB, IMATINIB, IMATINIB, NILOTINIB, ASCIMINIB, DASATINIB, DASATINIB, DASATINIB, DASATINIB, HYDROXYUREA, |
||||
| 16 | 26943387 |
TW |
64 | 2 |
Lung adenocarcinoma stage IV, Malignant neoplasm progression, Diarrhoea, Decreased appetite, Rash, Mucosal inflammation, Swelling of eyelid, Off label use, |
||||
TRAMETINIB, TRAMETINIB, TRAMETINIB, TRAMETINIB, GEFITINIB, GEFITINIB, |
||||
| 17 | 26943495 |
EU |
65 | 1 |
Malignant neoplasm progression, Immune-mediated hepatitis, Immune-mediated myasthenia gravis, Immune-mediated myocarditis, Immune-mediated myositis, |
||||
NIVOLUMAB, |
||||
| 18 | 26944039 |
EU |
70 | 1 |
Malignant neoplasm progression, Fatigue, |
||||
CARBOPLATIN, CARBOPLATIN, PEMBROLIZUMAB, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, BISOPROLOL FUMARATE, ERGOCALCIFEROL, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 19 | 26944403 |
EU |
94 | 2 |
Thyroid cancer, Malignant neoplasm progression, Dysphagia, Off label use, |
||||
TRAMETINIB, DABRAFENIB, |
||||
| 20 | 26944554 |
US |
1 | |
Malignant neoplasm progression, Abdominal discomfort, Rash, Nausea, |
||||
| 21 | 26944668 |
JP |
1 | |
Colitis, Malignant neoplasm progression, |
||||
TREMELIMUMAB, DURVALUMAB, DURVALUMAB, FEBUXOSTAT, FEBUXOSTAT TABLETS 40 MG, FEBUXOSTAT TABLETS 80 MG, AMLODIPINE, SULFASALAZINE, INSULIN DEGLUDEC, VONOPRAZAN FUMARATE, BETAMETHASONE DIPROPIONATE, |
||||
| 22 | 26944924 |
JP |
6 | 1 |
Colitis, Malignant neoplasm progression, |
||||
CABOZANTINIB, NIVOLUMAB, IPILIMUMAB, |
||||
| 23 | 26946183 |
EU |
2 | |
Malignant neoplasm progression, Therapeutic response shortened, |
||||
PEMBROLIZUMAB, |
||||
| 24 | 26947211 |
JP |
72 | 2 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 25 | 26934775 |
EU |
68 | 1 |
Pneumonia, Malignant neoplasm progression, Drug resistance, |
||||
OSIMERTINIB, |
||||
| 26 | 26934804 |
US |
54 | |
Malignant ascites, Haematological infection, Clostridium difficile infection, Vomiting, Malignant neoplasm progression, Nausea, |
||||
RELACORILANT, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), ACETAMINOPHEN AND CODEINE, RIMEGEPANT SULFATE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, PROMETHAZINE HYDROCHLORIDE, PROCHLORPERAZINE, VITAMIN C, |
||||
| 27 | 26935034 |
PK |
37 | 2 |
Malignant neoplasm progression, |
||||
BEVACIZUMAB, |
||||
| 28 | 26935153 |
JP |
||
Meningitis, Malignant neoplasm progression, Diarrhoea, |
||||
ZONGERTINIB, ZONGERTINIB, |
||||
| 29 | 26935264 |
JP |
2 | |
Malignant neoplasm progression, Small intestinal perforation, Therapy partial responder, Duodenal ulcer haemorrhage, |
||||
PEMBROLIZUMAB, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), CARBOPLATIN, BEVACIZUMAB, |
||||
| 30 | 26935396 |
JP |
1 | |
Death, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, |
||||
| 31 | 26935703 |
US |
61 | 2 |
Metastases to central nervous system, Breast cancer, Malignant neoplasm progression, Pneumonia, Confusional state, Metastases to meninges, Hypercalcaemia, Neuropathy peripheral, Carcinoembryonic antigen increased, Mitral valve thickening, Tricuspid valve incompetence, General physical health deterioration, Impaired work ability, Metastases to liver, Metastases to bone, Metastases to lung, Metastases to lymph nodes, Fatigue, Decreased appetite, Hepatic enzyme increased, Oedema peripheral, Weight decreased, Blood cholesterol increased, Asthenia, Lethargy, Feeling cold, Hilar lymphadenopathy, Drug intolerance, Dry skin, Oesophagitis, Radiation associated pain, Constipation, Taste disorder, Haemorrhoidal haemorrhage, Pollakiuria, Pain, Palpitations, Depression, Cough, Pyrexia, Incontinence, Aphasia, Crying, Anhedonia, Transaminases increased, Spinal pain, Stomatitis, Hot flush, Dyspepsia, Dizziness, Insomnia, Alopecia, Burning sensation, Diplopia, Hepatomegaly, Cholelithiasis, Pleural effusion, Lymphadenopathy mediastinal, Bone lesion, Vitamin D decreased, Monocyte count decreased, Blood chloride decreased, Blood urea decreased, Red blood cell count decreased, Alanine aminotransferase increased, Haematocrit decreased, Haemoglobin decreased, Blood albumin decreased, Mean cell haemoglobin decreased, Protein total decreased, Blood creatinine decreased, Blood sodium decreased, Blood calcium decreased, Lymphocyte count decreased, Lymphocyte count increased, Red cell distribution width increased, Carbohydrate antigen 15-3 increased, Blood calcium increased, Mean cell haemoglobin increased, Blood cholesterol increased, Mean cell volume increased, Blood triglycerides increased, Glycosylated haemoglobin increased, Low density lipoprotein increased, Non-high-density lipoprotein cholesterol increased, White blood cell count increased, Blood glucose increased, Blood alkaline phosphatase increased, Aspartate aminotransferase increased, Carbohydrate antigen 27.29 increased, Monocyte count increased, Platelet count increased, Mean cell haemoglobin concentration increased, Blood bilirubin increased, Neutrophil count increased, Prothrombin time prolonged, Urobilinogen urine increased, Protein urine present, Lung infiltration, Aortic valve sclerosis, Mitral valve calcification, Skin exfoliation, |
||||
EVEROLIMUS, LETROZOLE, LETROZOLE TABLETS, FAMOTIDINE, FULVESTRANT, FULVESTRANT, NAPROXEN SODIUM, NAPROXEN SODIUM 220MG, NAPROXEN SODIUM, COATED TABLETS, NAPROXEN SODIUM TABLET, COATED, ALPRAZOLAM, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE, METOROPROLOL TARTRATE, METOPROLOL, ATENOLOL, CAPECITABINE, CAPECITABINE, CAPECITABINE, CAPECITABINE, EXEMESTANE, DENOSUMAB, PALBOCICLIB, ALPRAZOLAM, ALPRAZOLAM, CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN, ESCITALOPRAM, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, PAROXETINE, PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE HEMIHYDRATE, GADOTERATE MEGLUMINE, GADOTERATE MEGLUMINE, FOLIC ACID, DOCUSATE SODIUM, DOCUSATE SODIUM 100MG, DOCUSATE SODIUM, DOCUSATE SODIUM 100MG, MORPHINE SULFATE, FERROUS SULFATE, LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE ANHYDROUS, LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE ANHYDROUS, |
||||
| 32 | 26936154 |
JP |
50 | 2 |
Malignant neoplasm progression, Anaemia, Malaise, |
||||
BELZUTIFAN, |
||||
| 33 | 26936402 |
EU |
71 | 2 |
Neuropathy peripheral, Malignant neoplasm progression, Radiotherapy, Surgery, |
||||
CARBOPLATIN, CARBOPLATIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), DOSTARLIMAB, DOSTARLIMAB, |
||||
| 34 | 26936878 |
CN |
76 | 1 |
Death, Gastrointestinal stromal tumour, Malignant neoplasm progression, Cardiac disorder, |
||||
| 35 | 26936970 |
JP |
6 | 1 |
Malignant neoplasm progression, Drug ineffective, |
||||
ENFORTUMAB VEDOTIN, |
||||
| 36 | 26937313 |
CH |
63 | 2 |
Impaired gastric emptying, Abdominal pain upper, Vomiting, Hypophagia, Dysphagia, Regurgitation, Linitis plastica, Hormone receptor positive HER2 negative breast cancer, Malignant neoplasm progression, Acute kidney injury, Inappropriate antidiuretic hormone secretion, Hyponatraemia, Hypotension, Metabolic disorder, Multiple organ dysfunction syndrome, Neutropenia, Lower limb fracture, Fall, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, RIBOCICLIB, RIBOCICLIB, |
||||
| 37 | 26937751 |
55 | 1 | |
Respiratory failure, Interstitial lung disease, Malignant neoplasm progression, |
||||
CETUXIMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), FAMOTIDINE, DEXAMETHASONE SODIUM PHOSPHATE, MAGNESIUM SULFATE, MAGNESIUM SULFATE HEPTAHYDRATE, MAGNESIUM SULFATE IN WATER FOR, DENOSUMAB, NAPROXEN, NAPROXEN SODIUM, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, LEMBOREXANT, NALDEMEDINE, MINOCYCLINE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE, OXYCODONE, OXYCODONE HYDROCHLORIDE, OXYCODONE, |
||||
| 38 | 26937776 |
EU |
65 | 1 |
Malignant neoplasm progression, |
||||
ENZALUTAMIDE, DOCETAXEL, DOCETAXEL ANHYDROUS, CABAZITAXEL, |
||||
| 39 | 26937855 |
CA |
71 | |
Malignant neoplasm progression, |
||||
AXICABTAGENE CILOLEUCEL, |
||||
| 40 | 26938075 |
RU |
2 | |
Malignant neoplasm progression, Breast cancer, Metastases to bone, Metastases to ovary, Hydrothorax, |
||||
ANASTROZOLE, ANASTROZOLE TABLETS, |
||||
| 41 | 26938167 |
AU |
2 | |
Malignant neoplasm progression, Ovarian cancer, Metastases to lymph nodes, Off label use, |
||||
LETROZOLE, LETROZOLE TABLETS, |
||||
| 42 | 26938210 |
NZ |
1 | |
Malignant neoplasm progression, Skin cancer, |
||||
TRAMETINIB, DABRAFENIB, |
||||
| 43 | 26938268 |
US |
50 | 1 |
Rectosigmoid cancer, Malignant neoplasm progression, |
||||
TUCATINIB, |
||||
| 44 | 26938702 |
EU |
73 | 1 |
Gastrointestinal stromal tumour, Malignant neoplasm progression, |
||||
| 45 | 26938816 |
39 | 2 | |
Malignant neoplasm progression, |
||||
FAM-TRASTUZUMAB DERUXTECAN-NXKI, |
||||
| 46 | 26939321 |
US |
80 | 1 |
Malignant neoplasm progression, Haemorrhage, Thrombocytopenia, Infection, |
||||
IVOSIDENIB, AZACITIDINE, AZACITIDINE FOR, |
||||
| 47 | 26939325 |
US |
84 | 2 |
Haemorrhage, Malignant neoplasm progression, Anaemia, Thrombocytopenia, |
||||
IVOSIDENIB, IVOSIDENIB, AZACITIDINE, AZACITIDINE FOR, AZACITIDINE, AZACITIDINE FOR, |
||||
| 48 | 26939432 |
JP |
9 | 1 |
Duodenal ulcer, Oropharyngeal pain, Cough, Malignant neoplasm progression, Inappropriate schedule of product administration, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 49 | 26939948 |
JP |
72 | 1 |
Pancreatic carcinoma, Malignant neoplasm progression, Off label use, |
||||
IMATINIB MESYLATE, IMATINIB, |
||||
| 50 | 26931383 |
TH |
84 | 1 |
Death, Monoplegia, Malignant neoplasm progression, |
||||
LANREOTIDE ACETATE, |
||||
| 51 | 26931670 |
EU |
50 | 1 |
Malignant neoplasm progression, Infusion related reaction, Therapy partial responder, |
||||
TRIFLURIDINE AND TIPIRACIL, BEVACIZUMAB, BEVACIZUMAB, BEVACIZUMAB, BEVACIZUMAB, PANITUMUMAB, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, CETUXIMAB, ENCORAFENIB, ENCORAFENIB, |
||||
| 52 | 26931672 |
IL |
71 | 2 |
Metastases to liver, Breast cancer metastatic, Malignant neoplasm progression, General physical health deterioration, Asthenia, Pain in jaw, Hypoaesthesia, Mastication disorder, Metastases to retroperitoneum, Osteonecrosis of jaw, Osteomyelitis, |
||||
RIBOCICLIB, LETROZOLE, LETROZOLE TABLETS, |
||||
| 53 | 26931682 |
US |
47 | 1 |
Sepsis, Cholecystitis acute, Malignant neoplasm progression, Abdominal pain, |
||||
CETUXIMAB, CETUXIMAB, CETUXIMAB, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE CAPSULE, LIQUID FILLED, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, PROCHLORPERAZINE, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, OXYCODONE, FAMOTIDINE, |
||||
| 54 | 26931860 |
CN |
54 | 1 |
Neutropenia, Malignant neoplasm progression, Hepatic failure, |
||||
PEMBROLIZUMAB, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, |
||||
| 55 | 26931912 |
CN |
71 | 1 |
Immune-mediated hepatic disorder, Immune-mediated myositis, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, |
||||
| 56 | 26932068 |
US |
17 | 2 |
Fungal sepsis, Malignant neoplasm progression, Enterococcal infection, |
||||
CALASPARGASE PEGOL, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYTARABINE, MERCAPTOPURINE, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 57 | 26932753 |
JP |
82 | 2 |
Female genital tract fistula, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 58 | 26933079 |
CA |
72 | 2 |
Malignant neoplasm progression, Fall, Contusion, Asthenia, Hospitalisation, Muscular weakness, Hypertension, Blood potassium decreased, Angioplasty, Malignant neoplasm progression, Gastric cancer, Headache, Migraine, Myalgia, Abdominal pain, Flatulence, Faeces discoloured, Nausea, Alopecia, Decreased appetite, Weight decreased, Breast discolouration, Insomnia, Pain in extremity, Off label use, Arthralgia, Diarrhoea, Abdominal pain upper, Off label use, Sinusitis, Eye infection, Anaemia, Pancreatic disorder, Vomiting, Nausea, Faeces discoloured, Abdominal pain upper, Polyp, Urinary tract infection, Fatigue, Diarrhoea, Abdominal distension, Stomach mass, Abdominal pain, Nausea, Vomiting, Diarrhoea, Fatigue, Polyp, Diarrhoea, Haemorrhoidal haemorrhage, Pain, Loss of personal independence in daily activities, Conjunctival laceration, Fall, Joint injury, Skin abrasion, Contusion, Pain, Fatigue, Pain, Nausea, Vomiting, Diarrhoea, Fall, Limb injury, Eye irritation, Walking aid user, Entropion, Asthenia, Fatigue, |
||||
LANREOTIDE ACETATE, LANREOTIDE ACETATE, LANREOTIDE ACETATE, LANREOTIDE ACETATE, LANSOPRAZOLE, CLONAZEPAM, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, CHOLESTYRAMINE, |
||||
| 59 | 26933184 |
US |
78 | 2 |
Toxicity to various agents, Malignant neoplasm progression, Febrile neutropenia, Sepsis, Haemorrhage, |
||||
IVOSIDENIB, AZACITIDINE, AZACITIDINE FOR, |
||||
| 60 | 26933185 |
US |
70 | 2 |
Toxicity to various agents, Malignant neoplasm progression, Sepsis, Neutropenia, Pneumonia, Haemorrhage, |
||||
IVOSIDENIB, AZACITIDINE, AZACITIDINE FOR, |
||||
| 61 | 26933186 |
US |
69 | 1 |
Toxicity to various agents, Malignant neoplasm progression, |
||||
IVOSIDENIB, AZACITIDINE, AZACITIDINE FOR, |
||||
| 62 | 26933187 |
US |
75 | 2 |
Malignant neoplasm progression, Haemorrhage, Neutropenia, Thrombocytopenia, |
||||
IVOSIDENIB, IVOSIDENIB, AZACITIDINE, AZACITIDINE FOR, |
||||
| 63 | 26933189 |
US |
76 | 1 |
Malignant neoplasm progression, Infection, Neutropenia, Thrombocytopenia, |
||||
IVOSIDENIB, IVOSIDENIB, AZACITIDINE, AZACITIDINE FOR, |
||||
| 64 | 26933191 |
US |
47 | 2 |
Malignant neoplasm progression, Sepsis, Product use issue, |
||||
IVOSIDENIB, DECITABINE, |
||||
| 65 | 26933261 |
EU |
57 | 2 |
Multiple organ dysfunction syndrome, Breast cancer metastatic, Malignant neoplasm progression, Emphysema, Femoral neck fracture, Cough, Dyspnoea, Back pain, |
||||
FULVESTRANT, FULVESTRANT, FULVESTRANT, RIBOCICLIB, RIBOCICLIB, |
||||
| 66 | 26933799 |
JP |
8 | |
Malignant neoplasm progression, |
||||
BLINATUMOMAB, |
||||
| 67 | 26926693 |
CN |
65 | 1 |
Immune-mediated lung disease, Pneumonia fungal, Respiratory failure, Malignant neoplasm progression, Anaemia, Cardio-respiratory arrest, |
||||
NIVOLUMAB, NIVOLUMAB, CISPLATIN, FLUOROURACIL CREAM, 0.5%, FLUOROURACIL, |
||||
| 68 | 26927034 |
BR |
66 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 69 | 26927390 |
AU |
2 | |
Hyperglycaemia, Malignant neoplasm progression, |
||||
CAPIVASERTIB, |
||||
| 70 | 26927400 |
MX |
53 | 2 |
Metastatic carcinoma of the bladder, Malignant neoplasm progression, |
||||
ENFORTUMAB VEDOTIN, PEMBROLIZUMAB, |
||||
| 71 | 26927401 |
JP |
2 | |
Malignant neoplasm progression, |
||||
OLAPARIB, |
||||
| 72 | 26927941 |
EU |
||
Death, General physical health deterioration, Malignant neoplasm progression, |
||||
SELINEXOR, |
||||
| 73 | 26928169 |
US |
32 | 2 |
Anaplastic large cell lymphoma T- and null-cell types, Metastases to central nervous system, Malignant neoplasm progression, |
||||
DOXORUBICIN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, CYTARABINE, BRENTUXIMAB VEDOTIN, METHOTREXATE SODIUM, DEXAMETHASONE SODIUM PHOSPHATE, CISPLATIN, PREDNISONE, |
||||
| 74 | 26928396 |
EU |
65 | 1 |
Malignant neoplasm progression, Metastases to liver, Diarrhoea, |
||||
CAPIVASERTIB, GOSERELIN, |
||||
| 75 | 26928477 |
US |
75 | 1 |
Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, CARBOPLATIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
| 76 | 26929032 |
EU |
68 | 1 |
Malignant neoplasm progression, |
||||
ENZALUTAMIDE, DENOSUMAB, |
||||
| 77 | 26929193 |
SG |
65 | 2 |
Malignant neoplasm progression, Drug ineffective, |
||||
TRASTUZUMAB, |
||||
| 78 | 26929380 |
EU |
50 | 2 |
Hepatic failure, Malignant neoplasm progression, Hypoglycaemia, |
||||
LANREOTIDE ACETATE, DIAZOXIDE, |
||||
| 79 | 26930111 |
61 | ||
Malignant neoplasm progression, |
||||
ELACESTRANT, |
||||
| 80 | 26930142 |
AU |
55 | 2 |
Cachexia, Compression fracture, Gastric antral vascular ectasia, Malignant neoplasm progression, Metastases to bone, Metastases to spine, Upper gastrointestinal haemorrhage, Adverse drug reaction, Blood chromogranin A increased, Blood glucose increased, Bone pain, Coagulopathy, Decreased appetite, Spinal pain, Back pain, |
||||
CAPECITABINE, ZOLEDRONIC ACID, OCTREOTIDE ACETATE, OCTREOTIDE, EVEROLIMUS, EVEROLIMUS TABLETS, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, STREPTOZOCIN, MITOMYCIN, |
||||
| 81 | 26921635 |
9 | 2 | |
Diffuse large B-cell lymphoma, Malignant neoplasm progression, Pyrexia, |
||||
EPCORITAMAB-BYSP, EPCORITAMAB-BYSP, |
||||
| 82 | 26921850 |
JP |
2 | |
Protein urine present, Malignant neoplasm progression, Immune-mediated hypothyroidism, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, LENVATINIB, LENVATINIB, LENVATINIB, LENVATINIB, CARBOPLATIN, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), |
||||
| 83 | 26921856 |
JP |
65 | |
Ureteric obstruction, Urinary tract infection, Lymphadenopathy, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 84 | 26921931 |
JP |
60 | 2 |
Death, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, |
||||
| 85 | 26922003 |
JP |
63 | 1 |
Bladder tamponade, Erythema, Malignant neoplasm progression, Therapy partial responder, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, ENFORTUMAB VEDOTIN, |
||||
| 86 | 26922199 |
EU |
56 | 1 |
Colitis, Malignant neoplasm progression, |
||||
NIVOLUMAB, IPILIMUMAB, |
||||
| 87 | 26922258 |
IN |
2 | |
Breast cancer metastatic, Malignant neoplasm progression, Neutropenia, Swelling, Pruritus, Product availability issue, Off label use, |
||||
RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, RIBOCICLIB, |
||||
| 88 | 26922387 |
JP |
2 | |
Malignant neoplasm progression, Intestinal perforation, Therapy partial responder, |
||||
PEMBROLIZUMAB, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), CARBOPLATIN, |
||||
| 89 | 26922509 |
JP |
78 | 2 |
Malignant neoplasm progression, Renal impairment, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, CARBOPLATIN, CARBOPLATIN, PEMETREXED, PEMETREXED DISODIUM, PEMETREXED, PEMETREXED DISODIUM, |
||||
| 90 | 26922669 |
EU |
62 | 2 |
Malignant neoplasm progression, |
||||
DURVALUMAB, OLAPARIB, |
||||
| 91 | 26922804 |
EU |
75 | 2 |
Malignant neoplasm progression, |
||||
BELZUTIFAN, |
||||
| 92 | 26922809 |
AU |
2 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 93 | 26923076 |
CN |
52 | 1 |
Myelosuppression, Malignant neoplasm progression, Septic shock, Febrile neutropenia, Escherichia infection, |
||||
PEMBROLIZUMAB, PEMBROLIZUMAB, PEMBROLIZUMAB, PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), PACLITAXEL, PACLITAXEL (AIBUMIN-BOUND), CISPLATIN, CISPLATIN, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, |
||||
| 94 | 26923231 |
JP |
1 | |
Malignant neoplasm progression, |
||||
ENZALUTAMIDE, |
||||
| 95 | 26923682 |
BR |
68 | |
Malignant neoplasm progression, |
||||
OSIMERTINIB, |
||||
| 96 | 26923712 |
US |
79 | 1 |
Malignant neoplasm progression, |
||||
AZACITIDINE, |
||||
| 97 | 26923841 |
JP |
75 | 2 |
Death, Immune-mediated enterocolitis, Immune-mediated nephritis, Blood pressure increased, Malaise, Therapy partial responder, Malignant neoplasm progression, |
||||
PEMBROLIZUMAB, LENVATINIB, |
||||
| 98 | 26924070 |
AU |
55 | 2 |
Death, Cachexia, Compression fracture, Gastric antral vascular ectasia, Malignant neoplasm progression, Metastases to bone, Metastases to spine, Upper gastrointestinal haemorrhage, Back pain, Blood chromogranin A increased, Blood glucose increased, Coagulopathy, Decreased appetite, Spinal pain, Bone pain, |
||||
CAPECITABINE, ZOLEDRONIC ACID, OCTREOTIDE ACETATE, OCTREOTIDE, EVEROLIMUS, EVEROLIMUS TABLETS, DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN, STREPTOZOCIN, MITOMYCIN, |
||||
| 99 | 26925537 |
80 | 2 | |
Pulmonary oedema, Malignant neoplasm progression, Interstitial lung disease, Anaemia, Aspartate aminotransferase increased, Alanine aminotransferase increased, SARS-CoV-2 test positive, |
||||
ABEMACICLIB, ANASTROZOLE, ANASTROZOLE TABLETS, DENOSUMAB, |
||||
| 100 | 26925821 |
EU |
64 | 1 |
Renal cell carcinoma, Malignant neoplasm progression, Metastases to lung, Metastases to lymph nodes, Metastases to soft tissue, |
||||
EVEROLIMUS, EVEROLIMUS TABLETS, EVEROLIMUS, EVEROLIMUS TABLETS, EVEROLIMUS, EVEROLIMUS TABLETS, EVEROLIMUS, EVEROLIMUS TABLETS, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30